$XBIO
Xenetic Biosciences, Inc.

2023 Q4 Form 10-Q Financial Statement

#000168316823007820 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $672.0K $611.2K
YoY Change 37.99% 47.54%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $952.0K $740.0K
YoY Change 11.06% -14.28%
% of Gross Profit
Research & Development $975.6K $1.021M
YoY Change -18.23% 155.92%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.928M $1.758M
YoY Change -5.98% 39.29%
Operating Profit -$1.147M
YoY Change 35.26%
Interest Expense $83.76K $90.00K
YoY Change 4.95% 97.89%
% of Operating Profit
Other Income/Expense, Net $400.00 $91.13K
YoY Change -59.6% 108.21%
Pretax Income -$1.172M -$1.060M
YoY Change -20.98% 31.84%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.172M -$1.056M
YoY Change -20.98% 31.29%
Net Earnings / Revenue -174.34% -172.71%
Basic Earnings Per Share -$0.69
Diluted Earnings Per Share -$0.76 -$0.69
COMMON SHARES
Basic Shares Outstanding 1.541M shares 1.533M shares
Diluted Shares Outstanding 1.533M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.983M $9.780M
YoY Change -31.41% -29.38%
Cash & Equivalents $8.983M $9.776M
Short-Term Investments
Other Short-Term Assets $603.8K $1.480M
YoY Change 8.58% 363.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.587M $11.26M
YoY Change -29.78% -20.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.018M $704.4K
YoY Change -4.55% -49.89%
Total Long-Term Assets $1.018M $704.4K
YoY Change -4.55% -49.89%
TOTAL ASSETS
Total Short-Term Assets $9.587M $11.26M
Total Long-Term Assets $1.018M $704.4K
Total Assets $10.61M $11.96M
YoY Change -27.96% -23.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $240.8K $448.6K
YoY Change -16.19% 121.21%
Accrued Expenses $568.8K $620.0K
YoY Change -27.62% -26.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $809.6K $1.068M
YoY Change -24.56% 1.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $809.6K $1.068M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $809.6K $1.068M
YoY Change -24.56% 1.68%
SHAREHOLDERS EQUITY
Retained Earnings -$193.2M -$192.1M
YoY Change 2.19% 2.37%
Common Stock $1.544K $1.536K
YoY Change -89.84% -89.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.796M $10.89M
YoY Change
Total Liabilities & Shareholders Equity $10.61M $11.96M
YoY Change -27.96% -23.19%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.172M -$1.056M
YoY Change -20.98% 31.29%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$794.2K -$950.0K
YoY Change 5.77% -11.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -794.2K -950.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities
Net Change In Cash -794.2K -950.0K
YoY Change 5.77% -11.98%
FREE CASH FLOW
Cash From Operating Activities -$794.2K -$950.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$794.2K -$950.0K
YoY Change 5.77% 64.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001534525
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37937
dei Entity Registrant Name
EntityRegistrantName
XENETIC BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2952962
dei Entity Address Address Line1
EntityAddressAddressLine1
945 Concord Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01701
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
778-7720
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1540684 shares
CY2023Q3 us-gaap Cash
Cash
9776073 usd
CY2022Q4 us-gaap Cash
Cash
13097265 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1480562 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
556094 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
11256635 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13653359 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
704431 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1066931 usd
CY2023Q3 us-gaap Assets
Assets
11961066 usd
CY2022Q4 us-gaap Assets
Assets
14720290 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
448558 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287360 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
619939 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
785796 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1068497 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1073156 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1068497 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1073156 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1535301 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1519360 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1532600 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1516659 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1536 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1520 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207978395 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207769904 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192062690 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189099618 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10892569 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11961066 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14720290 usd
CY2023Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
611174 usd
CY2022Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
414250 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1868023 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1219953 usd
CY2023Q3 us-gaap Revenues
Revenues
611174 usd
CY2022Q3 us-gaap Revenues
Revenues
414250 usd
us-gaap Revenues
Revenues
1868023 usd
us-gaap Revenues
Revenues
1219953 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1020618 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
398803 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2519137 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3577701 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
737241 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
863233 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2608934 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2796832 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1757859 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1262036 usd
us-gaap Operating Expenses
OperatingExpenses
5128071 usd
us-gaap Operating Expenses
OperatingExpenses
6374533 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1146685 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-847786 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3260048 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5154580 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-666 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1706 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24976 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2583 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
91796 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
45475 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
272000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
87345 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
91130 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
43769 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
296976 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
84762 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1055555 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-804017 usd
us-gaap Net Income Loss
NetIncomeLoss
-2963072 usd
us-gaap Net Income Loss
NetIncomeLoss
-5069818 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.64
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1532600 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1532600 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1431659 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1431659 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1524717 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1524717 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1394429 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1394429 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11877858 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
70266 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1055555 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10892569 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
xbio Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
208507 usd
us-gaap Net Income Loss
NetIncomeLoss
-2963072 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10892569 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15188921 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
137364 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-804017 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14522268 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
xbio Issuance Of Common Stock In Connection With Purchase Of Inprocess Research And Development
IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment
805000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
392829 usd
xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-5069818 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14522268 usd
us-gaap Net Income Loss
NetIncomeLoss
-2963072 usd
us-gaap Net Income Loss
NetIncomeLoss
-5069818 usd
xbio Research And Developments In Process
ResearchAndDevelopmentsInProcess
0 usd
xbio Research And Developments In Process
ResearchAndDevelopmentsInProcess
1305000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27043 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
208507 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
392829 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
924468 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-133253 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-362500 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
313920 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4659 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-370245 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3321192 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3895858 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
-0 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3321192 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4395858 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18244030 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9776073 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13848172 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
2 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
0 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
805000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 Reverse Stock Split
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q3 xbio Royalty Income Nonoperating1
RoyaltyIncomeNonoperating1
600000 usd
xbio Royalty Income Nonoperating1
RoyaltyIncomeNonoperating1
1900000 usd
CY2022Q3 xbio Royalty Income Nonoperating1
RoyaltyIncomeNonoperating1
400000 usd
xbio Royalty Income Nonoperating1
RoyaltyIncomeNonoperating1
1200000 usd
CY2023Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
78000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
300000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
70266 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
137364 usd
us-gaap Share Based Compensation
ShareBasedCompensation
208507 usd
us-gaap Share Based Compensation
ShareBasedCompensation
392829 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39200000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
27043 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
xbio-20230930_cal.xml Edgar Link unprocessable
xbio-20230930_def.xml Edgar Link unprocessable
0001683168-23-007820-index-headers.html Edgar Link pending
0001683168-23-007820-index.html Edgar Link pending
0001683168-23-007820.txt Edgar Link pending
0001683168-23-007820-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20230930.xsd Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xenetic_i10q-093023.htm Edgar Link pending
xbio-20230930_lab.xml Edgar Link unprocessable
xbio-20230930_pre.xml Edgar Link unprocessable
xenetic_i10q-093023_htm.xml Edgar Link completed